Dielsdorf, Switzerland, 10th April 2025:
Senn Chemicals AG (“Senn Chemicals”) announces the closing of the acquisition by Granules Peptides Private Limited, a wholly-owned subsidiary of Granules India Limited (“Granules”) today April 10th, 2025. The acquisition enables Senn Chemicals to support its future as a leading peptide manufacturing company.
Already back in February 2025, the Senn Family signed a share purchase agreement to transfer 100% of the shares of Senn Chemicals to Granules.
Since its founding over 60 years ago by Guido Senn, Senn Chemicals has been a private, family-owned Swiss CDMO specialising in peptides. After a careful evaluation of potential ownership transfer options, the family decided to sell the company to Granules, a vertically integrated pharmaceutical company, focused on manufacturing and selling of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).
A member of the Senn Family said, “The Senn family is pleased to have found a strong partner in Granules, who will lead the company into the future with strong growth and continue operations in Dielsdorf with the talented and experienced Senn Chemicals workforce.”
The Senn Chemicals brand and its site in Dielsdorf, Switzerland, will operate under Granules’ ownership, with a commitment to maintaining the company’s scientific excellence and customer focus.
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules, said, "The acquisition of Senn Chemicals AG marks a pivotal step in Granules’ strategic evolution into a science- and innovation-led organization. By entering the rapidly growing peptide therapeutics segment and building on Senn Chemical’s specialized CDMO capabilities, we are well-positioned to deliver high-quality, next-generation treatments. Senn Chemical’s specialized expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach. Together, we aim to drive meaningful impact in the complex therapeutics space."
The acquisition brings Senn Chemical’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments together with Granules’ market presence in India and the USA.
Together with Senn Chemical’s expertise Granules gains the capabilities into high-growth peptide based therapeutics. The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn Chemicals have active in the development of GLP-1 based APIs, and more peptide-based APIs are planned to be developed using Senn Chemical’s R&D capabilities.
The acquisition marks Granules foray into CDMO segments, leveraging Senn Chemical’s existing CDMO business and customer relationships, on back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn Chemical’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics. Senn Chemical’s presence in Europe provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules’ global footprint.
About Senn Chemicals
Senn Chemicals AG, located in Dielsdorf near Zurich, is a specialist in custom peptide manufacturing, supporting global clients across Pharmaceuticals, Cosmetics and Theragnostic industries, from early development to commercial production. With expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), Senn Chemicals offers development and manufacturing solutions for peptides, peptide fragments, and amino acid derivative (AAD). The company’s state-of-the-art capabilities include analytical method development, automated peptide synthesis, and scale-up expertise. Its cGMP and non-GMP manufacturing capabilities cover NCEs for clinical trials, kilo-scale production of cosmetic peptides, and AADs at commercial scale.
About Granules India Ltd. (BSE: 532482, NSE: GRANULES)
Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. Granules is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Granules products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 8 are in India and 2 in the USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.
About Hoffman & Partner and Kellerhals Carrard
Hoffmann & Partner (www.hoffmann-partner.com) acted as lead financial M&A advisor and Kellerhals Carrard (www.kellerhals-carrard.ch) as legal advisor of the sellers
